<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26232" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Opsoclonus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Margolin</surname>
            <given-names>Edward</given-names>
          </name>
          <aff>University of Toronto</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jeeva-Patel</surname>
            <given-names>Trishal</given-names>
          </name>
          <aff>University of Toronto</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edward Margolin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trishal Jeeva-Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26232.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Opsoclonus is an oculomotor dyskinesia characterized by rapid, repetitive conjugate eye movements that are involuntary, arrhythmic, chaotic, and multidirectional (horizontal, vertical, and torsional components) without intersaccadic intervals. This activity describes the evaluation and treatment of patients with opsoclonus and reviews the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of opsoclonus.</p></list-item><list-item><p>Review the appropriate evaluation of patients with opsoclonus.</p></list-item><list-item><p>Outline the management options available for patients with opsoclonus.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the care of patients with opsoclonus and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26232">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26232.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Opsoclonus is oculomotor dyskinesia characterized by rapid, repetitive conjugate eye movements that are involuntary, arrhythmic, chaotic, and multidirectional (horizontal, vertical, and torsional components) without intersaccadic intervals.<xref ref-type="bibr" rid="article-26232.r1">[1]</xref><xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r4">[4]</xref>&#x000a0;It is most pronounced when the patient is awake and attempting fixation. However, it persists during convergence and when eyelids are closed, in the dark, and during sleep.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref>&#x000a0;Visual blur and oscillopsia are common complaints in patients with opsoclonus due to the large amplitude and high frequency of the oscillations.</p>
        <p>Opsoclonus differs from opsochoria, which involves disconjugate eye movements&#x000a0;and ocular flutter, which is also an ocular dyskinesia that is restricted to the horizontal plane of eye movements.<xref ref-type="bibr" rid="article-26232.r1">[1]</xref><xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref>&#x000a0;Opsoclonus differs from nystagmus as the phase resulting in the eye movement away from the target is always a saccade.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref>&#x000a0;When opsoclonus presents with myoclonus and/or ataxia, encephalopathy, generalized tremor, or impaired cognition and behavioral changes, it is classified as an opsoclonus-myoclonus syndrome (OMS), which often is referred to as the &#x02018;dancing eye and dancing feet syndrome.'<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref></p>
      </sec>
      <sec id="article-26232.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Opsoclonus and OMS are associated with various disease entities, most commonly paraneoplastic syndromes, systemic infections, or due to toxic, metabolic, and drug-induced derangements. In adults, commonly described paraneoplastic etiologies include small cell lung cancer (SCLC), breast carcinoma, ovarian teratoma&#x02014;and, less frequently, non-Hodgkin lymphoma, malignant melanoma, and renal adenocarcinoma.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;One paper reviewed a large cohort of patients with opsoclonus and found that the probability of underlying neoplasm, other than an ovarian teratoma, is very low in patients who are younger than 40. In children, the most common etiology of opsoclonus and OMS are paraneoplastic neuroblastic tumors (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma), with over half of children with OMS harboring underlying neuroblastoma.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;</p>
        <p>Interestingly, the presence of opsoclonus in patients with neuroblastoma portends a&#x000a0;better prognosis.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;Other rare paraneoplastic etiologies of childhood opsoclonus include ovarian teratoma and hepatoblastoma.<xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;Para-infectious etiologies include human immunodeficiency virus (HIV) or immune reconstitution response to treatment initiation for HIV, <italic toggle="yes">Mycoplasma pneumoniae</italic>, <italic toggle="yes">Salmonella enterica</italic>, <italic toggle="yes">Rickettsia conorii</italic>, <italic toggle="yes">Streptococcus</italic>, Lyme disease, rotavirus, cytomegalovirus, human herpesvirus 6, hepatitis C, West Nile virus, and varicella-zoster virus.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;Other systemic diseases associated with opsoclonus include celiac disease, sarcoidosis, and multiple sclerosis.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref>&#x000a0;Toxins associated with the presence of opsoclonus include chlordecone, organophosphates, strychnine, thallium, and toluene.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref>&#x000a0;Medications associated with&#x000a0;opsoclonus include amitriptyline, cocaine, lithium, and phenytoin with diazepam.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref>&#x000a0;In many cases of opsoclonus, however, no etiology is found even after extensive investigations, and these cases are classified as idiopathic opsoclonus.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref></p>
      </sec>
      <sec id="article-26232.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Opsoclonus is very rare, with an annual incidence estimated to be 1 in 5 million.</p>
      </sec>
      <sec id="article-26232.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>While the exact pathophysiology of opsoclonus is unclear, three theories have been hypothesized. Considering that the abnormal eye movements are&#x000a0;saccadic in nature, the first theory hypothesizes that there may be underlying damage to omnipause neurons (ONs) in the pontine nucleus raphe interpositus, resulting in saccadic intrusions.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;ONs are responsible for preventing unwanted saccades by inhibiting burst cell neuronal stimulation in the paramedian pontine reticular formation (PPRF) and rostral interstitial nucleus of Cajal (riMLF), which are in turn responsible for initial saccadic command generation.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Thus, damage to ONs presumably results in uninhibited burst cell activity and subsequent involuntary ocular dyskinesia. However, to date, there has been no corroborating neuropathological evidence to support this theory, and proven lesions in the pontine nucleus raphe interpositus have been associated with slow saccades rather than abnormal oscillatory saccades.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref></p>
        <p>A second theory, the brainstem theory, postulates that the saccadic intrusions in opsoclonus&#x000a0;result from&#x000a0;the changes in the synaptic membrane properties of burst cells, predisposing them to either excessive post-inhibitory rebound excitation after sustained inhibition by ONs or alternatively rendering these burst cells unresponsive to the efficient ON inhibition.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Clinical correlation for this theory is lacking and such membrane changes would be expected to generate smaller amplitude saccadic oscillations compared to those seen in opsoclonus.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref></p>
        <p>The final theory is the cerebellar theory. It proposes that there are dysfunctional cerebellar Purkinje cells (PCs), which result in failure to inhibit the fastigial nucleus (FN) in the cerebellum, resulting in reinforcement of ONs inhibition and subsequent unopposed burst cell oscillation with resultant opsoclonus.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Increased activation of the FN seen on functional MRI and the presence of dysfunctional PCs on single-photon emission computed tomography (CT) seen in patients with opsoclonus are in favor of this theory.<xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Additionally, in the&#x000a0;case of OMS with myoclonic epilepsy, a heterozygous missense mutation with a large deletion in the potassium channel domain was identified and could further reinforce the cerebellum&#x02019;s role related to the pathophysiology of oscillatory saccades.<xref ref-type="bibr" rid="article-26232.r5">[5]</xref>. Last, this theory is further supported by the presence of histopathological evidence demonstrating damage to afferent projections to the fastigial nucleus in one patient with opsoclonus.<xref ref-type="bibr" rid="article-26232.r5">[5]</xref></p>
        <p>Recently, both humoral and cell-mediated immune mechanisms have been linked to paraneoplastic and idiopathic opsoclonus.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Additionally, the clinical response of patients with opsoclonus to immunosuppressive therapy is further suggestive of underlying immunological pathogenesis.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Humoral immunopathogenesis in paraneoplastic opsoclonus has been identified through the presence of numerous antineuronal antibodies, including anti-Ri (which is strongly associated with breast cancer), anti-Yo, anti-Hu, anti-Ma1, anti-Ma2, anti-amphiphysin, anti-CRMP-5/anti-CV2, anti-Zic2, anti-neurofilament (NF210K antibody), anti-neuroleukin, anti-gliadin (immunoglobulin A and G subtypes), anti-endomysial antibodies and anti-Purkinje cell antibodies.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r4">[4]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;</p>
        <p>Due to the variability of the presence of these&#x000a0;autoantibodies and many cases without any identifiable antibodies, it is unclear if their presence has any direct influence on the pathogenesis of opsoclonus or if they are merely an epiphenomenon of tumor presence.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;There is also no definitive link between the presence of these autoantibodies and&#x000a0;neurological abnormalities seen in OMS.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref>&#x000a0;Underlying cell-mediated immunopathogenesis has also been postulated to play a role&#x000a0;because&#x000a0;of the presence of lymphocytic pleocytosis in both serum and/or cerebrospinal fluid samples in some patients with opsoclonus.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;Clinical response to treatment with an anti-CD20 monoclonal antibody such as rituximab offers further support to this hypothesis.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r3">[3]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref></p>
      </sec>
      <sec id="article-26232.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A detailed history and a review of systems should be obtained in all patients in an attempt to uncover an underlying malignancy or recent infectious illness. Recording eye movements is useful as it allows the examiner to review the ocular motility in detail and confirm the diagnosis. Detailed neuro-ophthalmological assessment should be carried out in order to rule out any other associated abnormalities.</p>
      </sec>
      <sec id="article-26232.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Every patient presenting with opsoclonus or OMS requires comprehensive diagnostic investigation, including neuroimaging of the entire neuro-axis with contrast and a lumbar puncture. After the exclusion of central nervous system (CNS) disease, investigations for occult malignancy as well as toxic, metabolic, and para-infectious causes&#x000a0;must commence. A CT scan of the chest, abdomen, and pelvis should be performed in all patients, and if unrevealing, a positron emission tomography (PET) scan should ideally be performed in all patients, especially those older than 40.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r4">[4]</xref>&#x000a0;Even though autoantibody testing is of limited diagnostic value, it is still advocated as their presence would confirm&#x000a0;a diagnosis of paraneoplastic opsoclonus or OMS. In women, mammography and a thorough gynecological examination should be performed, and anti-Ri antibody titers should be checked.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r4">[4]</xref></p>
        <p>Investigating children with opsoclonus or OMS requires a detailed search for the presence of neuroblastoma. This includes imaging the entire neuro-axis with contrast and thin-cut CT of the chest, abdomen, and pelvis. Along with imaging,&#x000a0;urine catecholamine measurements, including vanillyl mandelic acid and homovanillic acid, should be performed in addition to the I-metaiodobenzylguanidine scan. Antibody screening should also be done&#x000a0;in children with common isolates being anti-neurofilament antibodies (NF210K antibody), anti-Purkinje cell antibodies, and immunoglobulin G autoantibodies.<xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;In all cases where the initial investigation is negative, repeat evaluation and re-investigation to exclude occult tumors should be undertaken a few months after the initial workup.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref></p>
      </sec>
      <sec id="article-26232.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Identifying the underlying etiology, particularly the presence of paraneoplastic syndrome, is paramount&#x000a0;in determining management and treatment outcomes. In those with proven cancer-associated opsoclonus or OMS, targeted cancer therapy (surgery, chemotherapy, and radiation) should be commenced and may be combined with immunotherapy when needed.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Given the underlying immunopathogenesis of opsoclonus, immunosuppression with corticosteroids (oral prednisone or intravenous dexamethasone pulses) or adrenocorticotropic hormone (ACTH) have proven to be efficacious and are usually administered in combination with intravenous immunoglobulin (IVIG) as the recent evidence demonstrated a higher response rate when IVIG was added to steroid therapy.<xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;In more severe cases, the use of cyclophosphamide or rituximab in conjunction with steroids or ACTH and IVIG has been described. Other immunotherapies and plasma exchange should be considered for those with refractory disease.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;In children, treatment for paraneoplastic opsoclonus also commonly involves the use of corticosteroids, ACTH, and IVIG. Low-dose cyclophosphamide or rituximab can be considered as an adjunct therapy in cases unresponsive to the above treatment, and plasmapheresis has proven useful in refractory cases.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref></p>
      </sec>
      <sec id="article-26232.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of OMS includes the following:</p>
        <p>Neurologic causes</p>
        <list list-type="bullet">
          <list-item>
            <p>Benign paroxysmal positional vertigo</p>
          </list-item>
          <list-item>
            <p>Cerebral vascular event</p>
          </list-item>
          <list-item>
            <p>Lateral medullary syndrome</p>
          </list-item>
          <list-item>
            <p>Meniere</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Tumors in the brain</p>
          </list-item>
          <list-item>
            <p>Wernicke encephalopathy</p>
          </list-item>
        </list>
        <p>Toxicologic causes</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol intoxication</p>
          </list-item>
          <list-item>
            <p>Amphetamines</p>
          </list-item>
          <list-item>
            <p>Barbiturates</p>
          </list-item>
          <list-item>
            <p>Benzodiazepines</p>
          </list-item>
          <list-item>
            <p>Ketamine</p>
          </list-item>
          <list-item>
            <p>Lithium</p>
          </list-item>
          <list-item>
            <p>Phencyclidine</p>
          </list-item>
          <list-item>
            <p>Phenytoin</p>
          </list-item>
          <list-item>
            <p>Salicylates</p>
          </list-item>
          <list-item>
            <p>Selective serotonin reuptake inhibitor toxicity</p>
          </list-item>
          <list-item>
            <p>Thiamine deficiency</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26232.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Intensive immunosuppression and remission are associated with an improved long-term neurological outcome. Approximately 75% of patients (especially children) with opsoclonus or OMS will experience relapses, especially related to the timing of tapering of immunosuppressive therapy. Relapses tend to be associated with worse long-term outcomes and, in children, often significant developmental sequelae; thus, the appropriate duration of treatment and cautious taper should be considered.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r5">[5]</xref>&#x000a0;Idiopathic opsoclonus tends to hold a better prognosis compared to those with paraneoplastic opsoclonus,&#x000a0;and in children, neuroblastoma in the presence of opsoclonus holds a better prognosis.<xref ref-type="bibr" rid="article-26232.r2">[2]</xref><xref ref-type="bibr" rid="article-26232.r6">[6]</xref>&#x000a0;All patients presenting with opsoclonus or OMS require extensive investigation to exclude the presence of occult tumors. Paraneoplastic opsoclonus in adults is commonly due to SCLC, breast carcinoma, or ovarian cancer, while in children, neuroblastoma is the most common etiology. Immunotherapy is key in preventing relapse and worsening neurological outcomes.</p>
      </sec>
      <sec id="article-26232.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Opsoclonus is an ocular dyskinesia with an elusive underlying humoral and cell-mediated immunopathogenesis. Falls&#x000a0;from imbalance can result in head and musculoskeletal injuries. Treatment with immunosuppressive agents can result in opportunistic infections. Developmental delay may occur in children with neuroblastoma and other tumors.</p>
      </sec>
      <sec id="article-26232.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Opsoclonus is an ocular dyskinesia with an elusive underlying humoral and cell-mediated immunopathogenesis. All patients presenting with opsoclonus or OMS require extensive investigation to exclude the presence of occult tumors. Paraneoplastic opsoclonus in adults is commonly due to SCLC, breast carcinoma, or ovarian cancer, while in children, neuroblastoma is the most common etiology. Immunotherapy is key in preventing relapse and worsening neurological outcomes.</p>
      </sec>
      <sec id="article-26232.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Individuals with opsoclonus may not recover, and emphasis should be placed on rehabilitation.&#x000a0;The involvement of therapists early in the course of the disease is important for optimal outcomes.&#x000a0;Interprofessional collaboration with the medical, radiation, and surgical oncologists, and infectious disease specialists, as well as with nurses and pharmacists, are required to enhance patient-centered care.</p>
      </sec>
      <sec id="article-26232.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26232">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/opsoclonus/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26232">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26232/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26232">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26232.s15">
        <title>References</title>
        <ref id="article-26232.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilgo</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Schwartze</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Opsoclonus. Update on clinical and pathologic associations.</article-title>
            <source>J Clin Neuroophthalmol</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-13</page-range>
            <pub-id pub-id-type="pmid">6233319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26232.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An update on opsoclonus.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-31</page-range>
            <pub-id pub-id-type="pmid">17215685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26232.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baloh</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Opsoclonus: clinical and immunological features.</article-title>
            <source>J Neurol Sci</source>
            <year>2012</year>
            <month>Sep</month>
            <day>15</day>
            <volume>320</volume>
            <issue>1-2</issue>
            <fpage>61</fpage>
            <page-range>61-5</page-range>
            <pub-id pub-id-type="pmid">22818114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26232.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sabater</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torres-Vega</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Hern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Planagum&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bataller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.</article-title>
            <source>JAMA Neurol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-24</page-range>
            <pub-id pub-id-type="pmid">26856612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26232.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dieterich</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on opsoclonus-myoclonus syndrome in adults.</article-title>
            <source>J Neurol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>266</volume>
            <issue>6</issue>
            <fpage>1541</fpage>
            <page-range>1541-1548</page-range>
            <pub-id pub-id-type="pmid">30483882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26232.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hero</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schleiermacher</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Update on pediatric opsoclonus myoclonus syndrome.</article-title>
            <source>Neuropediatrics</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>324</fpage>
            <page-range>324-9</page-range>
            <pub-id pub-id-type="pmid">24203854</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
